Early response to venlafaxine antidepressant correlates with lower ACTH levels prior to pharmacological treatment

A. V. Araya, P. Rojas, R. Fritsch, R. Rojas, L. Herrera, G. Rojas, H. Gatica, H. Silva, J. L. Fiedler

Resultado de la investigación: Article

9 Citas (Scopus)

Resumen

A link between stressful life events and development or exacerbation of depression has been established via a large body of evidence. An alteration in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis in depression has also been associated with an increase in cortisol secretion. As arginine-vasopressin (AVP) plays an important role in the activation of HPA axis during stress, the present study investigated ACTH and cortisol secretory response induced by an AVPrelated peptide desmopressin (ddAVP) in patients with major depression. Prior to antidepressant treatment, endocrinological parameters were evaluated and correlated with the clinical response to venlafaxine treatment, which offers a dual antidepressant action. Depressive patients with no other psychiatric pathology were evaluated with 17-item Hamilton Depression Scale (HAMD) in order to follow-up the response to venlafaxine. After 1 wk of treatment, 60% of patients reduced their initial HAM-D score to at least 25%; this group was classified as early responders. The other group (40%) started to reduce significantly their HAM-D score after 3 wk of treatment and was classified as late responders. After 6 wk of treatment both groups have reduced HAMD score to at least 25% of the baseline score. Prior to the pharmacological treatment, both early and late responders showed salivary cortisol rhythm and urinary free cortisol (UFC) in 24-h similar to healthy subjects. However, we did observe differences in basal ACTH secretion, showing that the late responder group had higher basal ACTH than both early responders and controls. The ddAVP challenge promoted a robust secretion of ACTH only in late responders, suggesting a different sensitivity of pituitary vasopressin receptor. The differences in clinical response to venlafaxine among depressive patients seem to be related to endocrinological parameters.

Idioma originalEnglish
Páginas (desde-hasta)289-297
Número de páginas9
PublicaciónEndocrine
Volumen30
N.º3
DOI
EstadoPublished - 1 dic 2006

Huella dactilar

Adrenocorticotropic Hormone
Antidepressive Agents
Pharmacology
Hydrocortisone
Therapeutics
Deamino Arginine Vasopressin
Vasopressin Receptors
Arginine Vasopressin
Psychiatry
Venlafaxine Hydrochloride
Healthy Volunteers
Pathology
Peptides

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Citar esto

Araya, A. V. ; Rojas, P. ; Fritsch, R. ; Rojas, R. ; Herrera, L. ; Rojas, G. ; Gatica, H. ; Silva, H. ; Fiedler, J. L. / Early response to venlafaxine antidepressant correlates with lower ACTH levels prior to pharmacological treatment. En: Endocrine. 2006 ; Vol. 30, N.º 3. pp. 289-297.
@article{f33aa614f08148f3aeb3701525c88247,
title = "Early response to venlafaxine antidepressant correlates with lower ACTH levels prior to pharmacological treatment",
abstract = "A link between stressful life events and development or exacerbation of depression has been established via a large body of evidence. An alteration in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis in depression has also been associated with an increase in cortisol secretion. As arginine-vasopressin (AVP) plays an important role in the activation of HPA axis during stress, the present study investigated ACTH and cortisol secretory response induced by an AVPrelated peptide desmopressin (ddAVP) in patients with major depression. Prior to antidepressant treatment, endocrinological parameters were evaluated and correlated with the clinical response to venlafaxine treatment, which offers a dual antidepressant action. Depressive patients with no other psychiatric pathology were evaluated with 17-item Hamilton Depression Scale (HAMD) in order to follow-up the response to venlafaxine. After 1 wk of treatment, 60{\%} of patients reduced their initial HAM-D score to at least 25{\%}; this group was classified as early responders. The other group (40{\%}) started to reduce significantly their HAM-D score after 3 wk of treatment and was classified as late responders. After 6 wk of treatment both groups have reduced HAMD score to at least 25{\%} of the baseline score. Prior to the pharmacological treatment, both early and late responders showed salivary cortisol rhythm and urinary free cortisol (UFC) in 24-h similar to healthy subjects. However, we did observe differences in basal ACTH secretion, showing that the late responder group had higher basal ACTH than both early responders and controls. The ddAVP challenge promoted a robust secretion of ACTH only in late responders, suggesting a different sensitivity of pituitary vasopressin receptor. The differences in clinical response to venlafaxine among depressive patients seem to be related to endocrinological parameters.",
keywords = "ACTH, AVP, Cortisol, CYP2D6*4, ddAVP, Depression, Venlafaxine",
author = "Araya, {A. V.} and P. Rojas and R. Fritsch and R. Rojas and L. Herrera and G. Rojas and H. Gatica and H. Silva and Fiedler, {J. L.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1007/s12020-006-0007-2",
language = "English",
volume = "30",
pages = "289--297",
journal = "Endocrine",
issn = "0969-711X",
publisher = "Humana Press",
number = "3",

}

Araya, AV, Rojas, P, Fritsch, R, Rojas, R, Herrera, L, Rojas, G, Gatica, H, Silva, H & Fiedler, JL 2006, 'Early response to venlafaxine antidepressant correlates with lower ACTH levels prior to pharmacological treatment', Endocrine, vol. 30, n.º 3, pp. 289-297. https://doi.org/10.1007/s12020-006-0007-2

Early response to venlafaxine antidepressant correlates with lower ACTH levels prior to pharmacological treatment. / Araya, A. V.; Rojas, P.; Fritsch, R.; Rojas, R.; Herrera, L.; Rojas, G.; Gatica, H.; Silva, H.; Fiedler, J. L.

En: Endocrine, Vol. 30, N.º 3, 01.12.2006, p. 289-297.

Resultado de la investigación: Article

TY - JOUR

T1 - Early response to venlafaxine antidepressant correlates with lower ACTH levels prior to pharmacological treatment

AU - Araya, A. V.

AU - Rojas, P.

AU - Fritsch, R.

AU - Rojas, R.

AU - Herrera, L.

AU - Rojas, G.

AU - Gatica, H.

AU - Silva, H.

AU - Fiedler, J. L.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - A link between stressful life events and development or exacerbation of depression has been established via a large body of evidence. An alteration in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis in depression has also been associated with an increase in cortisol secretion. As arginine-vasopressin (AVP) plays an important role in the activation of HPA axis during stress, the present study investigated ACTH and cortisol secretory response induced by an AVPrelated peptide desmopressin (ddAVP) in patients with major depression. Prior to antidepressant treatment, endocrinological parameters were evaluated and correlated with the clinical response to venlafaxine treatment, which offers a dual antidepressant action. Depressive patients with no other psychiatric pathology were evaluated with 17-item Hamilton Depression Scale (HAMD) in order to follow-up the response to venlafaxine. After 1 wk of treatment, 60% of patients reduced their initial HAM-D score to at least 25%; this group was classified as early responders. The other group (40%) started to reduce significantly their HAM-D score after 3 wk of treatment and was classified as late responders. After 6 wk of treatment both groups have reduced HAMD score to at least 25% of the baseline score. Prior to the pharmacological treatment, both early and late responders showed salivary cortisol rhythm and urinary free cortisol (UFC) in 24-h similar to healthy subjects. However, we did observe differences in basal ACTH secretion, showing that the late responder group had higher basal ACTH than both early responders and controls. The ddAVP challenge promoted a robust secretion of ACTH only in late responders, suggesting a different sensitivity of pituitary vasopressin receptor. The differences in clinical response to venlafaxine among depressive patients seem to be related to endocrinological parameters.

AB - A link between stressful life events and development or exacerbation of depression has been established via a large body of evidence. An alteration in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis in depression has also been associated with an increase in cortisol secretion. As arginine-vasopressin (AVP) plays an important role in the activation of HPA axis during stress, the present study investigated ACTH and cortisol secretory response induced by an AVPrelated peptide desmopressin (ddAVP) in patients with major depression. Prior to antidepressant treatment, endocrinological parameters were evaluated and correlated with the clinical response to venlafaxine treatment, which offers a dual antidepressant action. Depressive patients with no other psychiatric pathology were evaluated with 17-item Hamilton Depression Scale (HAMD) in order to follow-up the response to venlafaxine. After 1 wk of treatment, 60% of patients reduced their initial HAM-D score to at least 25%; this group was classified as early responders. The other group (40%) started to reduce significantly their HAM-D score after 3 wk of treatment and was classified as late responders. After 6 wk of treatment both groups have reduced HAMD score to at least 25% of the baseline score. Prior to the pharmacological treatment, both early and late responders showed salivary cortisol rhythm and urinary free cortisol (UFC) in 24-h similar to healthy subjects. However, we did observe differences in basal ACTH secretion, showing that the late responder group had higher basal ACTH than both early responders and controls. The ddAVP challenge promoted a robust secretion of ACTH only in late responders, suggesting a different sensitivity of pituitary vasopressin receptor. The differences in clinical response to venlafaxine among depressive patients seem to be related to endocrinological parameters.

KW - ACTH

KW - AVP

KW - Cortisol

KW - CYP2D64

KW - ddAVP

KW - Depression

KW - Venlafaxine

UR - http://www.scopus.com/inward/record.url?scp=34347360812&partnerID=8YFLogxK

U2 - 10.1007/s12020-006-0007-2

DO - 10.1007/s12020-006-0007-2

M3 - Article

C2 - 17526941

AN - SCOPUS:34347360812

VL - 30

SP - 289

EP - 297

JO - Endocrine

JF - Endocrine

SN - 0969-711X

IS - 3

ER -